Teva Launches Generic High Blood Pressure Drugs

Teva Pharmaceutical Industries has launched U.S. sales of irbesartan and irbesartan-hydrochlorothiazide tablets, generic versions of Sanofi Aventis' high blood pressure treatments Avapro and Avalide tablets.

The brand products had annual sales of $464 million and $124 million in the United States, based on sales data from the IMS research firm.

Israel-based Teva, the world's largest maker of generic drugs, has been awarded a 180-day period of marketing exclusivity, the company said on Monday.

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read